본문 바로가기
KERD
논문KCI 등재

A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization

명진종|Mattoo Sameer-ul-Salam
한국미생물·생명공학회 (The Korean Society For Microbiology And Biotechnology)|2021.12|Journal of Microbiology and Biotechnology|제31권 제12호|pp. 1601-1614|DOI 10.4014/jmb.2111.11026

0

조회

0

다운로드

2

인용

0

참고문헌

키워드

SARS-CoV-2variants of concernheterologus vaccinationhybrid immunity
주제분류생물학

초록

To overcome the ongoing COVID-19 pandemic, vaccination campaigns are the highest priority of majority of countries. Limited supply and worldwide disproportionate availability issues for the approved vaccines, together with concerns about rare side-effects have recently initiated the switch to heterologous vaccination, commonly known as mixing of vaccines. The COVID-19 vaccines are highly effective in the general population. However, none of the vaccines is 100% efficacious or effective, with variants posing more challenges, resulting in breakthrough cases. This review summarizes the current knowledge of immune responses to variants of concern (VOC) and breakthrough infections. Furthermore, we discuss the scope of heterologous vaccination and future strategies to tackle the COVID-19 pandemic, including fractionation of vaccine doses and alternative route of vaccination.

Abstract

To overcome the ongoing COVID-19 pandemic, vaccination campaigns are the highest priority of majority of countries. Limited supply and worldwide disproportionate availability issues for the approved vaccines, together with concerns about rare side-effects have recently initiated the switch to heterologous vaccination, commonly known as mixing of vaccines. The COVID-19 vaccines are highly effective in the general population. However, none of the vaccines is 100% efficacious or effective, with variants posing more challenges, resulting in breakthrough cases. This review summarizes the current knowledge of immune responses to variants of concern (VOC) and breakthrough infections. Furthermore, we discuss the scope of heterologous vaccination and future strategies to tackle the COVID-19 pandemic, including fractionation of vaccine doses and alternative route of vaccination.

참고문헌 (112)

  1. 안대균, "Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)", Journal of Microbiology and Biotechnology, 30(3), pp.313~324 (2020), 한국미생물·생명공학회
  2. Dagan N, "BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting", New England J. Med, 384, pp.1412~1423 (2021)
  3. Chemaitelly H, "Hasan MR, et al. 2021. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar", Nat. Med., 27, pp.1614~1621 (2021)
  4. Abu-Raddad LJ, "Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351variants", New England J. Med, 385, pp.187~189 (2021)
  5. Novak N, "Adverse rare events to vaccines for COVID-19: from hypersensitivity reactions to thrombosis and thrombocytopenia", Int. Rev. Immunol, pp.1~10 (2021)
  6. "Our World in D. 2021. Coronavirus (COVID-19) Vaccinations - Statistics and Research"[URL]
  7. "Tracking SARS-CoV-2 variants" (2021)[URL]
  8. Graham MS, "Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study", Lancet Public Health, 6, pp.e335~e345 (2021)
  9. Davies NG, "Estimated transmissibility and impact of SARSCoV-2 lineage B", Science, 372, pp.eabg3055~ (2021)
  10. Harvey WT, "SARS-CoV-2 variants, spike mutations and immune escape", Nat. Rev. Microbiol, 19, pp.409~424 (2021)
  11. Campbell F, "Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021", Eurosurveillance, 26, pp.2100509~ (2021)
  12. Faria NR, "Genomics and epidemiology of the P. 1 SARSCoV-2 lineage in Manaus, Brazil", Science, 372, pp.815~821 (2021)
  13. Cherian S, "SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India", Microorganisms, 9, pp.1542~ (2021)
  14. Chvatal-Medina M, "Antibody responses in COVID-19 : A Review", Front. Immunol, 12, pp.633184~ (2021)
  15. Cromer D, "Prospects for durable immune control of SARS-CoV2 and prevention of reinfection", Nat. Rev. Immunol, 21, pp.395~404 (2021)
  16. Sette A, "Adaptive immunity to SARS-CoV-2 and COVID-19", Cell, 184, pp.861~880 (2021)
  17. Weiskopf D, "Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome", Sci. Immunol, 5, pp.eabd2071~eabd2071 (2020)
  18. Neidleman J, "SARS-CoV-2-specific T cells exhibit phenotypic features of helper function, lack of terminal differentiation, and high proliferation potential", Cell Rep. Med, 1, pp.100081~100081 (2020)
  19. Sahin U, "COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses", Nature, 586, pp.594~599 (2020)
  20. Swanson PA, "T-cell mediated immunity after AZD1222vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire", medRxiv, ~ (2021)
  21. Painter MM, "Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination", Immunity, 54, pp.2133~2142. e213 (2021)
  22. Koutsakos M, "T follicular helper cells in the humoral immune response to SARS‐CoV‐2 infection and vaccination", J. Leukoc. Biol (2021)[DOI]
  23. Sekine T, "Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19", Cell, 183, pp.158~168. e114 (2020)
  24. Rydyznski Moderbacher C, "Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity", Cell, 183, pp.996~1012.e1019 (2020)
  25. Schulien I, "Characterization of pre-existing and induced SARSCoV-2-specific CD8(+)T cells", Nat. Med, 27, pp.78~85 (2021)
  26. Chen Y, "Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine", Clin. Microbiol. Infect (2021)[DOI]
  27. Planas D, "Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization", Nature, 596, pp.276~280 (2021)
  28. Supasa P, "Reduced neutralization of SARS-CoV-2 B. 1. 1. 7 variant by convalescent and vaccine sera", Cell, 184, pp.2201~2211.e2207 (2021)
  29. Zhou D, "Evidence of escape of SARS-CoV-2 variant B. 1. 351from natural and vaccine-induced sera", Cell, 184, pp.2348~2361. e234 (2021)
  30. Dejnirattisai W, "Antibody evasion by the P. 1 strain of SARS-CoV-2", Cell, 184, pp.2939~2954.e2939 (2021)
  31. Liu C, "Reduced neutralization of SARS-CoV-2 B. 1. 617 by vaccine and convalescent serum", Cell, 184, pp.4220~4236.e4213 (2021)
  32. Hoffmann M, "SARS-CoV-2 variants B. 1. 351 and P. 1 escape from neutralizing antibodies", Cell, 184, pp.2384~2393.e2312 (2021)
  33. Wu K, "Serum neutralizing activity elicited by mRNA1273 vaccine", New Engl. J. Med, 384, pp.1468~1470 (2021)
  34. Wall EC, "Neutralising antibody activity against SARS-CoV-2 VOCs B. 1. 617. 2 and B. 1. 351 by BNT162b2 vaccination", Lancet, 397, pp.2331~2333 (2021)
  35. Choi A, "Serum neutralizing activity of mRNA-1273 against SARSCoV-2 variants", J. Virol, 95, pp.e0131321~ (2021)
  36. Chen RE, "Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies", Nat. Med, 27, pp.717~726 (2021)
  37. Emary KRW, "Efficacy of ChAdOx1 nCoV-19(AZD1222)vaccine against SARS-CoV-2 variant of concern 202012", 01(B. 1. 1. 7) : an exploratory analysis of a randomised controlled trial, 2021, pp.397, 1351~1362
  38. Vacharathit V, "CoronaVac induces lower neutralising activity against variants of concern than natural infection", Lancet Infect. Dis, 21, pp.1352~1354 (2021)
  39. Jalkanen P, "COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants", Nat. Commun, 12, pp.3991~3991 (2021)
  40. Wang P, "Antibody resistance of SARS-CoV-2 variants B. 1. 351 and B. 1. 1. 7", Nature, 593, pp.130~135 (2021)
  41. Liu Y, "Neutralizing activity of BNT162b2-elicited serum", New Engl. J. Med, 384, pp.1466~1468 (2021)
  42. Alter G, "Immunogenicity of Ad26. COV2. S vaccine against SARS-CoV-2 variants in humans", Nature, 596, pp.268~272 (2021)
  43. Planas D, "Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies", Nat. Med, 27, pp.917~924 (2021)
  44. Hoffmann M, "SARS-CoV-2 variant B. 1. 617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination", Cell Rep, 36, pp.109415~ (2021)
  45. Liu J, "BNT162b2-elicited neutralization of B. 1. 617 and other SARS-CoV2 variants", Nature, 596, pp.273~275 (2021)
  46. Edara V-V, "Infection and vaccine-induced neutralizingantibody responses to the SARS-CoV-2 B.1.617 variants", New Engl. J. Med, 385, pp.664~666 (2021)
  47. Barouch DH, "Durable humoral and cellular immune responses 8months after Ad26.COV2.S vaccination", New Engl. J. Med, 385, pp.951~953 (2021)
  48. Liu G, "Predicted cellular immunity population coverage gaps for SARS-CoV-2 subunit vaccines and their augmentation by compact peptide sets", Cell Systems, 12, pp.102~107.e104 (2021)
  49. Corbett KS, "SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness", Nature, 586, pp.567~571 (2020)
  50. Tarke A, "Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals", Cell Rep. Med, 2, pp.100355~100355 (2021)
  51. Geers D, "SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees", Sci. Immunol, 6, pp.eabj1750~eabj1750 (2021)
  52. Agerer B, "SARS-CoV-2 mutations in MHC-Irestricted epitopes evade CD8(+)T cell responses", Sci. Immunol, 6, pp.eabag6461~ (2021)
  53. Lustig Y, "BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics : a prospective, single-centre, longitudinal cohort study in health-care workers", Lancet Respir. Med, 9, pp.999~1009 (2021)
  54. Bergwerk M, "Covid-19 breakthrough infections in vaccinated health care workers", New Engl. J. Med, 385, pp.1145~1146 (2021)
  55. Mallapaty S, "A blood marker predicts who gets ‘breakthrough’ COVID", Nature (2021)[DOI]
  56. Ulhaq ZS, "Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine", Indian J. Med. Microbiol, 39, pp.562~563 (2021)
  57. Selingerova I, "Interpretive discrepancies caused by target values inter-batch variations in chemiluminescence immunoassay for SARS-CoV-2 IgM", IgG by MAGLUMI, 2021, pp.93, 1805~1809
  58. Hacisuleyman E, "Vaccine breakthrough infections with SARS-CoV2 variants", New Engl. J. Med, 384, pp.2212~2218 (2021)
  59. Wise J, "Covid-19 : European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots", BMJ, 372, pp.n699~n699 (2021)
  60. Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1nCov-19 vaccination", New Engl. J. Med, 384, pp.2092~2101 (2021)
  61. Borobia AM, "Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants(CombiVacS) : a multicentre, open-label, randomised, controlled, phase 2trial", Lancet, 398, pp.121~130 (2021)
  62. Richardson CD, "Heterologous ChAdOx1-nCoV19?NT162b2 vaccination provides superior immunogenicity against COVID-19", Lancet Respir. Med, 314, pp.1936~1938 (2021)
  63. Benning L, "Heterologous ChAdOx1 nCoV-19", BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers, 2021, pp.9, 857~857
  64. Heath PT, "Safety and Efficacy of NVX-CoV2373 Covid-19 vaccine", New Engl. J. Med, 385, pp.1172~1183 (2021)
  65. Shaw RH, "Heterologous prime-boost COVID-19 vaccination : initial reactogenicity data", Lancet, 397, pp.2043~2046 (2021)
  66. Hillus D, "Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2 : a prospective cohort study", Lancet Respir. Med, 9, pp.918~918 (2021)
  67. Barros-Martins J, "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19", BNT162b2 vaccination, 2021, pp.27, 1525~1529
  68. Schmidt T, "Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19", mRNA vaccination, 2021, pp.27, 1530~1535
  69. Ostadgavahi AT, "Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response", J. Infect. Dev. Ctries, 15, pp.653~656 (2021)
  70. Mulligan MJ, "Phase I", II study of COVID-19 RNA vaccine BNT162b1 in adults, 2020, pp.586, 589~593
  71. Liu X, "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine(Com-COV) : a single-blind, randomised, non-inferiority trial", Lancet(London, England), 398, pp.856~869 (2021)
  72. Jara A, "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile", New Engl. J. Med, 385, pp.875~884 (2021)
  73. Crotty S, "Hybrid immunity", Science, 372, pp.1392~1393 (2021)
  74. Tan C-W, "Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors", N. Engl. J. Med, 385, pp.1401~1406 (2021)
  75. Stamatatos L, "mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection", Science, 25, pp.eabg9175~ (2021)
  76. Goel RR, "Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination", Sci. Immunol, 6, pp.eabi6950~ (2021)
  77. 배소정, "Chikungunya Virus nsP2 Impairs MDA5", RIG-I-Mediated Induction of NF-κB Promoter Activation: A Potential Target for Virus-Specific Therapeutics, 2020, pp.30(12), 1801~1809[DOI]
  78. Nguyen Thi Thuy Ngan, "Zika Virus Proteins NS2A and NS4A Are Major Antagonists that Reduce IFN-β Promoter Activity Induced by the MDA5", RIG-I Signaling Pathway, 2019, pp.29(10), 1665~1674[DOI]
  79. 명진종, "Dose-Dependent Inhibition of Melanoma Differentiation-Associated Gene 5-Mediated Activation of Type I Interferon Responses by Methyltransferase of Hepatitis E Virus", Journal of Microbiology and Biotechnology, 29(7), pp.1137~1143 (2019), 한국미생물·생명공학회[DOI]
  80. 명진종, "Beyond Viral Interferon Regulatory Factors: Immune Evasion Strategies", Journal of Microbiology and Biotechnology, 29(12), pp.1873~1881 (2019), 한국미생물·생명공학회[DOI]
  81. Jinjong Myoung, "Methyltransferase of a cell culture-adapted hepatitis E inhibits the MDA5 receptor signaling pathway", The Journal of Microbiology, 57(12), pp.1126~1131 (2019), 한국미생물학회[DOI]
  82. 이정윤, "Middle East Respiratory Syndrome Coronavirus-Encoded ORF8b Inhibits RIG-I-Like Receptors by a Differential Mechanism", Journal of Microbiology and Biotechnology, 29(12), pp.2014~2021 (2019), 한국미생물·생명공학회[DOI]
  83. Jeong Yoon Lee, "Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design", The Journal of Microbiology, 57(9), pp.803~811 (2019), 한국미생물학회[DOI]
  84. 이정윤, "Middle East Respiratory Syndrome Coronavirus-Encoded Accessory Proteins Impair MDA5-and TBK1-Mediated Activation of NF-κB", Journal of Microbiology and Biotechnology, 29(8), pp.1316~1323 (2019), 한국미생물·생명공학회[DOI]
  85. 이정윤, "Generation of Full-Length Infectious cDNA Clones of Middle East Respiratory Syndrome Coronavirus", Journal of Microbiology and Biotechnology, 29(6), pp.999~1007 (2019), 한국미생물·생명공학회[DOI]
  86. Cowling BJ, "Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality", Nat. Med, 27, pp.1321~1323 (2021)
  87. "Interim statement on dose-sparing strategies for COVID-19 vaccines (fractionated vaccine doses)" (2021)[URL]
  88. Wu JT, "Fractional dosing of yellow fever vaccine to extend supply : a modelling study", Lancet(London, England), 388, pp.2904~2911 (2016)
  89. WHO, "WHO position on the use of fractional doses-June 2017, addendum to vaccines and vaccination against yellow fever WHO : Position paper-June 2013", Vaccine, 35, pp.5751~5752 (2017)
  90. Chu L, "A preliminary report of a randomized controlled phase 2trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine", Vaccine, 39, pp.2791~2799 (2021)
  91. Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
  92. Callaway E, "COVID vaccine boosters : the most important questions", Nature, 596, pp.178~180 (2021)
  93. Turner JS, "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses", Nature, 596, pp.109~113 (2021)
  94. Krause PR, "Considerations in boosting COVID-19 vaccine immune responses", Lancet(London, England), 6736, pp.21~24 (2021)
  95. Tregoning JS, "Progress of the COVID-19 vaccine effort : viruses, vaccines and variants versus efficacy, effectiveness and escape", Nat. Rev. Immunol, 21, pp.626~636 (2021)
  96. Sekine T, "Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19", Cell, 183, pp.158~168.e114 (2020)
  97. Gallais F, "Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France", Emerg. Infect. Dis, 27, pp.113~121 (2021)
  98. Yang J, "Characteristics of T-cell responses in COVID-19 patients with prolonged SARS-CoV-2 positivity – a cohort study", Clin. Transl. Immunol, 10, pp.e1259~e1259 (2021)
  99. Jeyanathan M, "Immunological considerations for COVID-19 vaccine strategies", Nat. Rev. Immunol, 20, pp.615~632 (2020)
  100. Szabo PA, "Location, location, location: Tissue resident memory T cells in mice and humans", Sci. Immunol, 4, pp.eaas9673~eaas9673 (2019)
  101. Jeyanathan M, "New Tuberculosis vaccine strategies : taking aim at un-natural immunity", Trends Immunol, 39, pp.419~433 (2018)
  102. Hassan AO, "A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2", Cell, 183, pp.169~184.e113 (2020)
  103. Pizzolla A, "Memory T cell dynamics in the lung during influenza virus infection", J. Immunol, 202, pp.374~381 (2019)
  104. Brinkley-Rubinstein L, "Breakthrough SARS-CoV-2 infections in prison after vaccination", N. Engl. J. Med, 385, pp.1051~1052 (2021)
  105. Kustin T, "Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals", Nat. Med, 27, pp.1379~1384 (2021)
  106. Niyas VKM, "Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine", QJM : Int. J. Med, 114, pp.757~758 (2021)
  107. Butt AA, "Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination", Int. J. Infect. Dis, 110, pp.353~358 (2021)
  108. Lange B, "Breakthrough infections in BNT162b2-vaccinated health care workers", N. Engl. J. Med, 385, pp.1145~1146 (2021)
  109. Duerr R, "Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City", J. Clin. Invest, 131, pp.e152702~ (2021)
  110. Estofolete CF, "Case study of two post vaccination SARS-CoV-2 infections with P1 variants in coronaVac vaccinees in Brazil", Viruses, 13, pp.1237~1237 (2021)
  111. Ioannou P, "Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers", Infect. Dis, 53, pp.876~879 (2021)
  112. Martinot M, "Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination", Clin. Microbiol. Infect, 27, pp.1537~1539 (2021)

관련 논문AI추천

A Meta-Analysis on the Immunogenicity of Homologous versus Heterologous Immunization Regimens against SARS-CoV-2 Beta, Delta, and Omicron BA.1 VoCs in Healthy AdultsFan Xiong-lin, Kamara Abdul A., Lei Qing, Ndzouboukou Jo-Lewis Banga, Ullah Nadeem한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2025 · 제35권 코로나19 범유행을 대비하기 위한 이종교차접종의 선택김태형대한내과학회 · 대한내과학회지2021 · 제96권 제6호Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses구근본, 김균도, 김성준, 김천생, 이수민, 황인수한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2020 · 제30권 제8호Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative reviewJae Kyung Lee, Ok Sarah Shin영남대학교 의과대학 · Journal of Yeungnam Medical Science2022 · 제39권 제2호Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in KoreaChoi Eun Bee, Do Hyeon Nam, In Hyun Ju, Jang Sundong, Kim Byoungguk, Kim Byung Chul, Kim Kwangwook, Kim Soo Ji, Lee June-Woo, Lee Yoo-kyoung, Lim Heeji, Lim Hye Jung, Ouh In-ohk, Yim Min Su대한감염학회 · Infection and Chemotherapy2023 · 제55권 제1호Pre-existing Immunity to Endemic Human Coronaviruses Does Not Affect the Immune Response to SARS-CoV-2 Spike in a Murine Vaccination Model김두진, Jeong Ahn Young, Lee Moo-Seung, Lee Pureum대한면역학회 · Immune Network2023 · 제23권 제2호

이 간행물의 다른 논문 (7건)

Picropodophyllotoxin Induces G1 Cell Cycle Arrest and Apoptosis in Human Colorectal Cancer Cells via ROS Generation and Activation of p38 MAPK Signaling Pathway심정현, Lee Mee-Hyun, Joo Sang Hoon, Yoon Goo, Seo Ji-Hye, Chae Jung-Il, 조성식, Lee Seung-On, Kwak Ah-Wonpp. 1615-1623Enhanced Large-Scale Production of Hahella chejuensis-Derived Prodigiosin and Evaluation of Its BioactivityKim Suran, 이상준, 정세규, Kim Hyun Ju, Park Seo-Young, 이무승, Jeong Yujin, Kim HyeRanpp. 1624-1631Anti-Tuberculosis Activity of Pediococcus acidilactici Isolated from Young Radish Kimchi against Mycobacterium tuberculosisRahim MD Abdur, Seo Hoonhee, Kim Sukyung, Lee Saebim, 송호연, Yoon Youjin, Lee Youngkyoungpp. 1632-1642Green Synthesis of Copper Nano-Drug and Its Dental Application upon Periodontal Disease-Causing MicroorganismsEl-Rab Sanaa M. F. Gad, Basha Sakeenabi, Ashour Amal A., Enan Enas Tawfik, Alyamani Amal Ahmed, Felemban Nayef H.pp. 1656-1666Effect of High Hydrostatic Pressure Treatment on Urease Activity and Inhibition of Fishy Smell in Mackerel (Scomber japonicus) during StorageXU Xiaotong, Jeong So-Mi, 안동현, Kim Han-Ho, Ryu Si-Hyeong, Kang Woo-Sin, Lee Ji-Eun, Kim Su-Ryong, Lee Ga-Hyepp. 1684-1691
원문 보기